Lyka Labs Valuation

Q: What is the Fair Price of 500259 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

500259 (₹146.15) is trading above our estimate of [[fair value]] (₹0.48)

Is 500259 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 500259 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 500259 (₹146.15) is trading above our estimate of fair value (₹0.48)

Significantly Below Fair Value: 500259 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 500259?

Key metric: As 500259 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 500259. This is calculated by dividing 500259's market cap by their current revenue.
What is 500259's PS Ratio?
PS Ratio	4.1x
Sales	₹1.27b
Market Cap	₹5.23b

500259 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.4x
Enterprise Value/EBITDA	36.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 500259's PS Ratio compare to its peers?

The above table shows the PS ratio for 500259 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.9x
ACCENTMIC Accent Microcell	1.9x	n/a	₹5.1b
VALIANTLAB Valiant Laboratories	4.4x	n/a	₹4.9b
500009 Ambalal Sarabhai Enterprises	2.4x	n/a	₹4.3b
INFINIUM Infinium Pharmachem	2.9x	n/a	₹4.6b
500259 Lyka Labs	4.1x	n/a	₹5.2b

Price-To-Sales vs Peers: 500259 is expensive based on its Price-To-Sales Ratio (4.1x) compared to the peer average (2.9x).

Price to Sales Ratio vs Industry

How does 500259's PS Ratio compare vs other companies in the IN Pharmaceuticals Industry?

13 Companies	Price / Sales	Estimated Growth	Market Cap
NECLIFE Nectar Lifesciences	0.4x	n/a	US$87.68m
539561 Remedium Lifecare	0.07x	n/a	US$27.94m
532637 Mangalam Drugs & Organics	0.5x	n/a	US$19.96m
531173 Syschem (India)	0.5x	n/a	US$18.63m

13 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 500259 is expensive based on its Price-To-Sales Ratio (4.1x) compared to the Indian Pharmaceuticals industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is 500259's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

500259 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 500259's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Venus Remedies

₹3.9b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹294.55

-0.4%

-21.5%

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

-45.9%

Sanofi India

₹143.0b

Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.

SANOFI

₹6,210.00

0.6%

-22.7%